EXELIXIS, INC. (NASDAQ:EXEL) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
Exelixis, Inc. ("Exelixis") held its 2018 Annual Meeting of Stockholders (the "Annual Meeting") on May23, 2018, at its offices located at 210 East Grand Avenue, South San Francisco, CA 94080. At the Annual Meeting, Exelixis stockholders were asked to vote upon:
|
1. |
The election of each of three Class I directors for a three-year term until the 2021 annual meeting of stockholders. The nominees for election to these positions were Charles Cohen, Ph.D., George Poste, DVM, Ph.D., FRS and Jack L. Wyszomierski; |
|
2. |
The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending December 28, 2018; and |
|
3. |
The approval, on an advisory basis, of the compensation of Exelixis’ named executive officers, as disclosed in Exelixis’ definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 12, 2018 (the "Proxy Statement"). |
The voting results of the matters presented at the Annual Meeting are as follows:
|
1. |
The election of each of Charles Cohen, Ph.D., George Poste, DVM, Ph.D., FRS and Jack L. Wyszomierski as directors of Exelixis until the 2021 annual meeting of stockholders, and until his successor is elected and qualified, or until his earlier death, resignation or removal, was approved as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
|
Charles Cohen, Ph.D. |
195,675,036 |
10,128,865 |
274,990 |
60,113,905 |
|
George Poste, DVM, Ph.D., FRS |
196,217,735 |
9,582,786 |
278,370 |
60,113,905 |
|
Jack L. Wyszomierski |
195,579,418 |
10,197,061 |
302,412 |
60,113,905 |
Exelixis’ Class II directors, Carl B. Feldbaum, Esq., Maria C. Freire, Ph.D, Alan M. Garber, M.D., Ph.D., Vincent T. Marchesi, M.D., Ph.D. and Julie Anne Smith, will each continue to serve on the Board of Directors until the 2019 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal. Exelixis’ Class III directors, Michael M. Morrissey, Ph.D., Stelios Papadopoulos, Ph.D., George A. Scangos, Ph.D. and Lance Willsey, M.D. will each continue to serve on the Board of Directors until the 2020 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal.
|
2. |
The ratification of Ernst& Young LLP as the Exelixis independent registered public accounting firm for the fiscal year ending December 28, 2018, was approved as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
261,388,865 |
2,845,006 |
1,958,925 |
|
3. |
The compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement, received advisory approval as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
157,477,795 |
42,276,914 |
6,324,182 |
60,113,905 |
About EXELIXIS, INC. (NASDAQ:EXEL)
Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.
